Who are Donepezil (Aricept)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aricept, Midodrine + pyridostigmine, Galantamine (Reminyl), Neostigmine with glycopyrrolate, Propranolol+pyridostigmine, Donepezil HCI (drug).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/donepezil-aricept.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Donepezil (Aricept) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Donepezil (Aricept) (Donepezil (Aricept)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholinesterase Inhibitor. Area: Neuroscience.

marketed Acetylcholinesterase Inhibitor Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Donepezil (Aricept) (Donepezil (Aricept)) — University of Virginia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Donepezil (Aricept) TARGET	Donepezil (Aricept)	University of Virginia	marketed	Acetylcholinesterase Inhibitor	Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon
Aricept	Aricept	Eisai Korea Inc.	marketed		Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon
Midodrine + pyridostigmine	Midodrine + pyridostigmine	Seoul National University Hospital	marketed	Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination	Alpha-1 adrenergic receptor; acetylcholinesterase
Galantamine (Reminyl)	Galantamine (Reminyl)	Janssen-Cilag Pty Ltd	marketed	Acetylcholinesterase inhibitor with nicotinic receptor modulation	Acetylcholinesterase; nicotinic acetylcholine receptors
Neostigmine with glycopyrrolate	Neostigmine with glycopyrrolate	The Cleveland Clinic	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase; muscarinic acetylcholine receptors
Propranolol+pyridostigmine	Propranolol+pyridostigmine	Seoul National University Hospital	marketed	Beta-blocker + Acetylcholinesterase inhibitor combination	Beta-adrenergic receptors; Acetylcholinesterase
Donepezil HCI (drug)	Donepezil HCI (drug)	Neurognostics	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase (AChE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Acetylcholinesterase Inhibitor class)

University of Virginia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Donepezil (Aricept) — Competitive Intelligence Brief. https://druglandscape.com/ci/donepezil-aricept. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing